

UNITED STATES INTERNATIONAL TRADE COMMISSION
Washington, DC 20436

**MEMORANDUM ON PROPOSED TARIFF LEGISLATION
of the 110th Congress¹**

[Date approved: May 16, 2008]²

Bill No. and sponsor: H.R. 4677 (Mr. Christopher S. Murphy of Connecticut and Mr. Christopher Shays of Connecticut).

Proponent name,³ location: Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT.

Other bills on product (110th Congress only): None.

Nature of bill: Temporary duty suspension through December 31, 2011.

Retroactive effect: None.

Suggested article description(s) for enactment (including appropriate HTS subheading(s)):

2-Cyclopropylaminonicotinic acid (CAS No. 639807-18-4) (provided for in subheading 2933.39.61).

Check one: ___ Same as that in bill as introduced.
 X Different from that in bill as introduced (see Technical comments section).

Product information, including uses/applications and source(s) of imports:

The subject product is a synthetic organic chemical that is used as an intermediate in the production of a drug that treats HIV. The proponent imports this chemical from France.

Estimated effect on customs revenue:

HTS subheading: <u>2933.39.61</u>					
 	2009	2010	2011	2012	2013
Col. 1-General rate of duty	6.5%	6.5%	6.5%	6.5%	6.5%
Estimated value <i>dutiable</i> imports	\$1,200,000	\$1,200,000	\$1,200,000	\$1,200,000	\$1,200,000
Customs revenue loss	\$78,000	\$78,000	\$78,000	\$78,000	\$78,000

Source of estimated dutiable import data: U.S. industry estimates.

Contacts with domestic firms/organizations (including the proponent):

¹ Industry analyst preparing report: Philip Stone (202-205-3424); Tariff Affairs contact: David Michels (202-205-3440).

² Access to an electronic copy of this memorandum is available at http://www.usitc.gov/tata/hts/other/rel_doc/bill_reports/.

³ The sponsor/proponent did not identify any additional beneficiaries of this bill.

Name of firm/organization	Date contacted	Claim US makes same or competing product(s)?	Submission attached?	Opposition noted?
		(Yes/No)		
Boehringer Ingelheim Pharmaceuticals (Proponent) Henry Menn, Email: HMenn@brownrudnick.com	03/19/2008	No	No	No
Abbott Laboratories Claude Burcky, Fax: 202-783-6631	03/19/2008	No	No	No
Bayer Corp. Karen Niedermeyer, Fax: 412-777-4740 Julie Van Egmund, Fax: 202-737-8909	03/19/2008	No	No	No
Bristol Myers Squibb Company David Warr, Fax: 202-783-2308	03/19/2008	No	No	No
Clariant Corporation Andrew Zamoyski, Fax: 202-248-9043	03/19/2008	No	No	No
DuPont Helen McMahon, Fax: 302-355-2994	03/19/2008	No	No	No
Eli Lilly Kathy Karol, Fax: 202-624-9460	03/19/2008	No	No	No
Endo Pharmaceuticals Albert McCorwick, Fax: 484-840-4277	03/19/2008	No	No	No
Gilead Sciences Cheryl Myriad, Fax: 650-522-5853	03/19/2008	No	No	No
GlaxoSmithKline William Schuyler, Fax: 202-715-1001	03/19/2008	No	No	No
Interferon Sciences, Inc. Samuel Ronel, Fax: 732-249-6895	03/19/2008	No	No	No
Lonza Inc. Cheryl Prescott, Fax: 201-696-3558	03/19/2008	No	No	No
Merck Thomas Bombelles, Fax: 202-638-3670	03/19/2008	No	No	No
Monsanto Grant Erdel, Fax: 202-789-1867	03/19/2008	No	No	No
Niche Pharmaceuticals Steve Brandon, Fax: 817-491-3533	03/19/2008	No	No	No
Novartis Tracy Haller, Fax: 202-628-4763	03/19/2008	No	No	No

Name of firm/organization	Date contacted	Claim US makes same or competing product(s)?	Submission attached?	Opposition noted?
Pfizer Katherine Bennett, Fax: 202-347-2044	03/19/2008	No	No	No
Procter and Gamble Jim McCarthy, Fax: 202-393-4606	03/19/2008	No	No	No
Schering-Plough Rob Lively, Fax: 202-463-8809	03/19/2008	No	No	No
Watson Sarah Sweet, Fax: 951-270-1429	03/19/2008	No	No	No

Technical comments:⁴

The Commission staff suggests the article description on page 1 of this report be used because it contains the correct chemical name.

⁴ The Commission may express an opinion on the HTS classification of a product to facilitate consideration of the bill. However, by law, only the U.S. Customs Service is authorized to issue a binding ruling on this matter. The Commission believes that the U.S. Customs Service should be consulted prior to enactment of the bill.

110TH CONGRESS
1ST SESSION

H. R. 4677

To suspend temporarily the duty on Cyclopropylaminonicotinic acid.

IN THE HOUSE OF REPRESENTATIVES

DECEMBER 13, 2007

Mr. MURPHY of Connecticut (for himself and Mr. SHAYS) introduced the following bill; which was referred to the Committee on Ways and Means

A BILL

To suspend temporarily the duty on
Cyclopropylaminonicotinic acid.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. CYCLOPROPYLAMINONICOTINIC ACID.**

4 (a) IN GENERAL.—Subchapter II of chapter 99 of
5 the Harmonized Tariff Schedule of the United States is
6 amended by inserting in numerical sequence the following
7 new heading:

“	9902.01.00	Cyclopropylaminonicotinic acid (2-CAN) (CAS No. 639807–18–4) (provided for in subheading 2933.39.61) ..	Free	No change	No change	On or before 12/31/2011	”.
---	------------	---	------	-----------	-----------	-------------------------	----

1 (b) EFFECTIVE DATE.—The amendment made by
2 subsection (a) applies to articles entered, or withdrawn
3 from warehouse for consumption, on or after the 15th day
4 after the date of the enactment of this Act.

○